Tarsus Pharmaceuticals, Inc.
TARS
Rangering i aksjer
#4594
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aksjekurs
$71.12
Sist synkronisert: 2026-10-20
Markedsverdi
$3.33B
Endring (1 dag)
2.33%
Endring (1 år)
0.42%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
P/S-forhold for Tarsus Pharmaceuticals, Inc. (TARS)
P/S-forhold per October 2026 TTM: 5.13
Ifølge Tarsus Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 5.13. Ved slutten av 2023 hadde selskapet et P/S-forhold på 34.10.
P/S-historikk for Tarsus Pharmaceuticals, Inc. fra 2018 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 5.13 | -54.93% |
| 2024 | 11.38 | -66.63% |
| 2023 | 34.10 | 143.94% |
| 2022 | 13.98 | 72.40% |
| 2021 | 8.11 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | 95.38% |
US
|
|
| 40.55 | 690.54% |
US
|
|
| 3.96 | -22.78% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 97.80% |
NL
|
